Assessment of the Worldwide Antimalarial Resistance Network Standardized Procedure for In Vitro Malaria Drug Sensitivity Testing Using SYBR Green Assay for Field Samples with Various Initial Parasitemia Levels.

Autor:	Cheruiyot AC; Department of Emerging Infectious Diseases-Global Emerging Infections Surveillance and Response System (DEID-GEIS) Program, U.S. Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)-Walter Reed Project, Kisumu, Kenya., Auschwitz JM; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Lee PJ; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Yeda RA; Department of Emerging Infectious Diseases-Global Emerging Infections Surveillance and Response System (DEID-GEIS) Program, U.S. Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)-Walter Reed Project, Kisumu, Kenya., Okello CO; Department of Emerging Infectious Diseases-Global Emerging Infections Surveillance and Response System (DEID-GEIS) Program, U.S. Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)-Walter Reed Project, Kisumu, Kenya., Leed SE; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Talwar M; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Murthy T; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Gaona HW; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Hickman MR; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Akala HM; Department of Emerging Infectious Diseases-Global Emerging Infections Surveillance and Response System (DEID-GEIS) Program, U.S. Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)-Walter Reed Project, Kisumu, Kenya., Kamau E; Department of Emerging Infectious Diseases-Global Emerging Infections Surveillance and Response System (DEID-GEIS) Program, U.S. Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)-Walter Reed Project, Kisumu, Kenya., Johnson JD; Department of Emerging Infectious Diseases-Global Emerging Infections Surveillance and Response System (DEID-GEIS) Program, U.S. Army Medical Research Directorate-Kenya (USAMRD-K), Kenya Medical Research Institute (KEMRI)-Walter Reed Project, Kisumu, Kenya jacob.d.johnson.mil@mail.mil.
Jazyk:	angličtina
Zdroj:	Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2016 Mar 25; Vol. 60 (4), pp. 2417-24. Date of Electronic Publication: 2016 Mar 25 (Print Publication: 2016).
DOI:	10.1128/AAC.00527-15
Abstrakt:	The malaria SYBR green assay, which is used to profilein vitrodrug susceptibility ofPlasmodium falciparum, is a reliable drug screening and surveillance tool. Malaria field surveillance efforts provide isolates with various low levels of parasitemia. To be advantageous, malaria drug sensitivity assays should perform reproducibly among various starting parasitemia levels rather than at one fixed initial value. We examined the SYBR green assay standardized procedure developed by the Worldwide Antimalarial Resistance Network (WWARN) for its sensitivity and ability to accurately determine the drug concentration that inhibits parasite growth by 50% (IC50) in samples with a range of initial parasitemia levels. The initial sensitivity determination of the WWARN procedure yielded a detection limit of 0.019% parasitemia.P. falciparumlaboratory strains and field isolates with various levels of initial parasitemia were then subjected to a range of doses of common antimalarials. The IC50s were comparable for laboratory strains with between 0.0375% and 0.6% parasitemia and for field isolates with between 0.075% and 0.6% parasitemia for all drugs tested. Furthermore, assay quality (Z') analysis indicated that the WWARN procedure displays high robustness, allowing for drug testing of malaria field samples within the derived range of initial parasitemia. The use of the WWARN procedure should allow for the inclusion of more malaria field samples in malaria drug sensitivity screens that would have otherwise been excluded due to low initial parasitemia levels. (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu